ALNY vs. DXCM: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at ALNY and DXCM, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Overview
ALNY’s market capitalization stands at 43.28 billion USD, while DXCM’s is 32.52 billion USD, indicating their market valuations are broadly comparable.
DXCM carries a higher beta at 1.46, indicating it’s more sensitive to market moves, while ALNY (beta: 0.21) exhibits greater stability.
| Symbol | ALNY | DXCM |
|---|---|---|
| Company Name | Alnylam Pharmaceuticals, Inc. | DexCom, Inc. |
| Country | US | US |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Medical - Devices |
| CEO | Yvonne L. Greenstreet | Kevin Ronald Sayer |
| Price | 331.91 USD | 82.93 USD |
| Market Cap | 43.28 billion USD | 32.52 billion USD |
| Beta | 0.21 | 1.46 |
| Exchange | NASDAQ | NASDAQ |
| IPO Date | June 1, 2004 | April 14, 2005 |
| ADR | No | No |
Historical Performance
This chart compares the performance of ALNY and DXCM by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period.
Data is adjusted for dividends and splits.
Profitability
Return on Equity
ALNY
-509.33%
Biotechnology Industry
- Max
- 72.39%
- Q3
- -6.30%
- Median
- -32.82%
- Q1
- -68.26%
- Min
- -147.61%
ALNY has a negative Return on Equity of -509.33%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
DXCM
24.38%
Medical - Devices Industry
- Max
- 49.04%
- Q3
- 9.53%
- Median
- -7.46%
- Q1
- -32.83%
- Min
- -82.64%
In the upper quartile for the Medical - Devices industry, DXCM’s Return on Equity of 24.38% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
Return on Invested Capital
ALNY
-2.79%
Biotechnology Industry
- Max
- 48.74%
- Q3
- -10.68%
- Median
- -31.65%
- Q1
- -52.92%
- Min
- -113.69%
ALNY has a negative Return on Invested Capital of -2.79%. This indicates that its operations are failing to generate a profit on the total capital invested, signaling significant inefficiency or value destruction.
DXCM
9.42%
Medical - Devices Industry
- Max
- 21.88%
- Q3
- 6.63%
- Median
- -1.11%
- Q1
- -21.08%
- Min
- -51.95%
In the upper quartile for the Medical - Devices industry, DXCM’s Return on Invested Capital of 9.42% signifies a highly effective use of its capital to generate profits when compared to its peers.
Net Profit Margin
ALNY
-11.49%
Biotechnology Industry
- Max
- 87.75%
- Q3
- -5.05%
- Median
- -103.44%
- Q1
- -1,032.77%
- Min
- -2,366.07%
ALNY has a negative Net Profit Margin of -11.49%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
DXCM
12.90%
Medical - Devices Industry
- Max
- 44.80%
- Q3
- 9.77%
- Median
- -5.53%
- Q1
- -29.37%
- Min
- -87.68%
A Net Profit Margin of 12.90% places DXCM in the upper quartile for the Medical - Devices industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin
ALNY
-4.91%
Biotechnology Industry
- Max
- 87.75%
- Q3
- -3.28%
- Median
- -115.26%
- Q1
- -1,188.86%
- Min
- -2,943.30%
ALNY has a negative Operating Profit Margin of -4.91%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
DXCM
15.25%
Medical - Devices Industry
- Max
- 30.13%
- Q3
- 13.12%
- Median
- 3.47%
- Q1
- -24.42%
- Min
- -80.56%
An Operating Profit Margin of 15.25% places DXCM in the upper quartile for the Medical - Devices industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
| Symbol | ALNY | DXCM |
|---|---|---|
| Return on Equity (TTM) | -509.33% | 24.38% |
| Return on Assets (TTM) | -6.40% | 7.93% |
| Return on Invested Capital (TTM) | -2.79% | 9.42% |
| Net Profit Margin (TTM) | -11.49% | 12.90% |
| Operating Profit Margin (TTM) | -4.91% | 15.25% |
| Gross Profit Margin (TTM) | 86.01% | 59.39% |
Financial Strength
Current Ratio
ALNY
3.04
Biotechnology Industry
- Max
- 28.73
- Q3
- 13.97
- Median
- 6.31
- Q1
- 3.60
- Min
- 0.02
ALNY’s Current Ratio of 3.04 falls into the lower quartile for the Biotechnology industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
DXCM
1.50
Medical - Devices Industry
- Max
- 12.68
- Q3
- 6.30
- Median
- 4.05
- Q1
- 1.85
- Min
- 0.01
DXCM’s Current Ratio of 1.50 falls into the lower quartile for the Medical - Devices industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
Debt-to-Equity Ratio
ALNY
11.28
Biotechnology Industry
- Max
- 0.46
- Q3
- 0.22
- Median
- 0.06
- Q1
- 0.02
- Min
- 0.00
With a Debt-to-Equity Ratio of 11.28, ALNY operates with exceptionally high leverage compared to the Biotechnology industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.
DXCM
1.14
Medical - Devices Industry
- Max
- 2.34
- Q3
- 1.09
- Median
- 0.37
- Q1
- 0.08
- Min
- 0.00
DXCM’s leverage is in the upper quartile of the Medical - Devices industry, with a Debt-to-Equity Ratio of 1.14. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.
Interest Coverage Ratio
ALNY
-0.79
Biotechnology Industry
- Max
- 108.32
- Q3
- -0.55
- Median
- -8.49
- Q1
- -74.83
- Min
- -168.36
ALNY has a negative Interest Coverage Ratio of -0.79. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
DXCM
43.93
Medical - Devices Industry
- Max
- 18.18
- Q3
- 7.53
- Median
- 0.85
- Q1
- -9.80
- Min
- -33.94
With an Interest Coverage Ratio of 43.93, DXCM demonstrates a superior capacity to service its debt, placing it well above the typical range for the Medical - Devices industry. This stems from either robust earnings or a conservative debt load.
Financial Strength at a Glance
| Symbol | ALNY | DXCM |
|---|---|---|
| Current Ratio (TTM) | 3.04 | 1.50 |
| Quick Ratio (TTM) | 2.98 | 1.32 |
| Debt-to-Equity Ratio (TTM) | 11.28 | 1.14 |
| Debt-to-Asset Ratio (TTM) | 0.31 | 0.38 |
| Net Debt-to-EBITDA Ratio (TTM) | -1.85 | 1.89 |
| Interest Coverage Ratio (TTM) | -0.79 | 43.93 |
Growth
The following charts compare key year-over-year (YoY) growth metrics for ALNY and DXCM. These metrics are based on the companies’ annual financial reports.
Revenue Growth
Earnings Per Share (EPS) Growth
Free Cash Flow Growth
Dividend
Dividend Yield
ALNY
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ALNY currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
DXCM
0.00%
Medical - Devices Industry
- Max
- 3.57%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
DXCM currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio
ALNY
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ALNY has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
DXCM
0.00%
Medical - Devices Industry
- Max
- 102.12%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
DXCM has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | ALNY | DXCM |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
Price-to-Earnings Ratio
ALNY
-159.59
Biotechnology Industry
- Max
- 78.44
- Q3
- 48.98
- Median
- 20.50
- Q1
- 12.64
- Min
- 2.14
ALNY has a negative P/E Ratio of -159.59. This occurs when a company has negative earnings (a net loss), making the ratio unsuitable for valuation analysis.
DXCM
60.60
Medical - Devices Industry
- Max
- 90.56
- Q3
- 56.92
- Median
- 43.19
- Q1
- 21.79
- Min
- 5.55
A P/E Ratio of 60.60 places DXCM in the upper quartile for the Medical - Devices industry. This high valuation relative to peers suggests the market holds elevated expectations for the company’s future growth.
Forward P/E to Growth Ratio
ALNY
-43.29
Biotechnology Industry
- Max
- 2.29
- Q3
- 1.10
- Median
- 0.49
- Q1
- 0.16
- Min
- 0.02
ALNY has a negative Forward PEG Ratio of -43.29. This typically results from negative earnings or forecasts of declining future earnings, making the ratio not meaningful for valuation.
DXCM
2.77
Medical - Devices Industry
- Max
- 6.56
- Q3
- 3.52
- Median
- 2.22
- Q1
- 0.55
- Min
- 0.03
DXCM’s Forward PEG Ratio of 2.77 is within the middle range of its peers in the Medical - Devices industry. This suggests a reasonable balance between the stock’s price and its expected growth, aligning with sector valuation norms.
Price-to-Sales Ratio
ALNY
18.43
Biotechnology Industry
- Max
- 110.90
- Q3
- 59.76
- Median
- 11.33
- Q1
- 4.45
- Min
- 0.17
ALNY’s P/S Ratio of 18.43 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
DXCM
7.84
Medical - Devices Industry
- Max
- 15.74
- Q3
- 8.12
- Median
- 3.40
- Q1
- 2.37
- Min
- 0.42
DXCM’s P/S Ratio of 7.84 aligns with the market consensus for the Medical - Devices industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio
ALNY
372.86
Biotechnology Industry
- Max
- 15.78
- Q3
- 7.44
- Median
- 3.31
- Q1
- 1.58
- Min
- 0.31
The P/B Ratio is often not a primary valuation metric for the Biotechnology industry.
DXCM
14.31
Medical - Devices Industry
- Max
- 16.65
- Q3
- 8.03
- Median
- 3.73
- Q1
- 1.92
- Min
- 0.65
DXCM’s P/B Ratio of 14.31 is in the upper tier for the Medical - Devices industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.
Valuation at a Glance
| Symbol | ALNY | DXCM |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | -159.59 | 60.60 |
| Forward PEG Ratio (TTM) | -43.29 | 2.77 |
| Price-to-Sales Ratio (P/S, TTM) | 18.43 | 7.84 |
| Price-to-Book Ratio (P/B, TTM) | 372.86 | 14.31 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | -574.08 | 56.53 |
| EV-to-EBITDA (TTM) | -285.32 | 38.43 |
| EV-to-Sales (TTM) | 18.55 | 8.24 |